By Professor Michael Leonard Friedlander

Conference Papers

Konstantinopoulos P; Gonzalez-Martin A; Cruz F; Friedlander M; Glasspool R; Lorusso D; Marth C; Monk B; Kim J-W; Ajipa O; Su F; Han Y; Matulonis U, 2022, 'TP030/#1426 EPIK-O/ENGOT-OV61: a phase 3, randomized study of alpelisib + olaparib in patients with no germline BRCA mutation detected, platinum-resistant or -refractory, high-grade serous ovarian cancer', in E-Posters (Trials In Progress), BMJ Publishing Group Ltd, presented at IGCS 2022 Annual Meeting Abstracts, http://dx.doi.org/10.1136/ijgc-2022-igcs.539

Xu X; Wang Y; Bryce N; Tang K; Meagher NS; Kang EY; Kelemen LE; Köbel M; Ramus SJ; Friedlander M; Ford CE; Hardeman EC; Gunning PW, 2021, 'Abstract 1045: Combined targeting of actin/tropomyosin and microtubules underlies a potential treatment strategy of epithelial ovarian cancer with cell-cycle dependent synergy', in Cancer Research, American Association for Cancer Research (AACR), pp. 1045 - 1045, http://dx.doi.org/10.1158/1538-7445.am2021-1045

Xu X; Wang Y; Bryce N; Tang K; Meagher NS; Kang EY; Kelemen LE; Kobel M; Ramus SJ; Friedlander M; Ford CE; Hardeman EC; Gunning PW, 2021, 'Combined targeting of actin/tropomyosin and microtubules underlies a potential treatment strategy of epithelial ovarian cancer with cell-cycle dependent synergy.', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000680263503257&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Wildiers H; Ayoub J-P; Friedlander M; Kaufman B; Arun BK; Han HS; Puhalla SL; Maag D; Feng D; Ratajczak CK; Bach BA; Diéras V, 2021, 'Abstract PS11-03: Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: A subgroup analysis of germline BRCA1 or BRCA2 mutations from the phase 3 BROCADE3 trial', in Cancer Research, American Association for Cancer Research (AACR), http://dx.doi.org/10.1158/1538-7445.sabcs20-ps11-03

Colombo N; Bradley W; Moore K; Gonzalez-Martin A; Scambia G; Oaknin A; Friedlander M; Lowe E; Rowe P; Disilvestro P, 2020, 'MAINTENANCE OLAPARIB IN PATIENTS WITH NEWLY DIAGNOSED ADVANCED OVARIAN CANCER AND A BRCA MUTATION: SUBGROUP ANALYSIS BY RISK IN THE PHASE III SOLO1 STUDY', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, BMJ PUBLISHING GROUP, pp. A76 - A77, http://dx.doi.org/10.1136/ijgc-2020-ESGO.130

Friedlander ML; Moore K; Colombo N; Scambia G; Kim B-G; Oaknin A; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza A; Gonzalez-Martin A; Aghajanian C; Bradley W; Holmes E; Lowe ES; Disilvestro P, 2020, 'Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, pp. S1334 - S1334, presented at ESMO Asia Virtual Congress, ELECTR NETWORK, 20 November 2020 - 22 November 2020, http://dx.doi.org/10.1016/j.annonc.2020.10.228

Meiser B; Gleeson M; Kentwell M; Do J; Nevin S; Taylor N; Barlow-Stewart K; Kirk J; James P; Scott CL; Williams R; Gamet K; Burke J; Murphy M; Antill Y; Pearn A; Pachter N; Ebzery C; Poplawski N; Friedlander M; Tucker K, 2020, 'The development and evaluation of a nationwide training program for oncology health professionals in the provision of genetic testing for ovarian cancer patients', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 62 - 62, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000790145400011&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Swisher EM; Coleman RL; Bookman MA; Brady MF; Fleming GF; Friedlander M; Cunningham MJ; Tewari KS; Edraki B; Moxley K; Mantia-Smaldone GM; Ratajczak C; Dinh MH; Sullivan DM; McClain S; Okubo S; Steffensen KD; Aghajanian C, 2020, 'Safety of veliparib in combination with chemotherapy and as maintenance in front-line ovarian cancer: Results in BRCAm, hrd, and whole populations from the velia trial', in GYNECOLOGIC ONCOLOGY, ACADEMIC PRESS INC ELSEVIER SCIENCE, pp. 20 - 21, http://dx.doi.org/10.1016/j.ygyno.2020.06.040

Banerjee S; Moore KN; Colombo N; Scambia G; Kim B-G; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Oza A; Gonzalez Martin A; Aghajanian C; Bradley W; Holmes E; Lowe ES; DiSilvestro P, 2020, 'Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, pp. S613 - S613, presented at ESMO Virtual Congress, ELECTR NETWORK, 19 September 2020 - 18 October 2020, http://dx.doi.org/10.1016/j.annonc.2020.08.950

Yoon W-H; Kok PS; Marschner I; Lord S; Friedlander M; Lee CK, 2020, 'Objective response rate as an intermediate surrogate endpoint to predict overall survival at 12 months', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, pp. S715 - S715, presented at ESMO Virtual Congress, ELECTR NETWORK, 19 September 2020 - 18 October 2020, http://dx.doi.org/10.1016/j.annonc.2020.08.1162

Macdonald C; Mazza D; Hickey M; Hunter M; Keogh LA; Jones SC; Saunders C; Nesci S; Milne RL; McLachlan SA; Hopper J; Friedlander M; Emery J; Phillips KA, 2020, 'The cognitive, affective, social and environmental drivers of inappropriate ovarian cancer screening: A survey of women and their clinicians using the theoretical domains framework', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, pp. S958 - S958, presented at ESMO Virtual Congress, ELECTR NETWORK, 19 September 2020 - 18 October 2020, http://dx.doi.org/10.1016/j.annonc.2020.08.2057

Ayoub J-P; Friedlander ML; Dieras VC; Wildiers H; Arun B; Han HS; Puhalla S; Shparyk Y; Jakobsen EH; Kundu MG; Wu M; Ratajczak C; Maag D; Kaufman B, 2020, 'Veliparib plus carboplatin-paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: Results in hormone receptor-positive and triple-negative breast cancer subgroups from the phase III BROCADE3 trial', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, pp. S65 - S65, presented at ESMO Breast Cancer Virtual Meeting, ELECTR NETWORK, 23 May 2020 - 24 May 2020, http://dx.doi.org/10.1016/j.annonc.2020.03.241

Sivakumaran T; Krasovitsky M; Freimund A; Chen Lee K; Webber K; So J; Norris C; Friedlander M; Mileshkin L; Au-Yeung G, 2020, '402 Treatment patterns post PARP inhibitor in epithelial ovarian cancer patients: results from an Australian, retrospective, multi-institute cohort study', in Poster, BMJ Publishing Group Ltd, presented at IGCS 2020 Annual Meeting Abstracts, http://dx.doi.org/10.1136/ijgc-2020-igcs.347

Sivakumaran T; Krasovitsky M; Lee YC; Norris C; Friedlander M, 2020, '403 Treatment patterns post PARP inhibitor in epithelial ovarian cancer patients: results from an Australian, retrospective, multi-institute cohort study', in Poster, BMJ Publishing Group Ltd, presented at IGCS 2020 Annual Meeting Abstracts, http://dx.doi.org/10.1136/ijgc-2020-igcs.348

Friedlander ML, 2019, 'Do all patients with recurrent ovarian cancer need systemic therapy?', in Cancer, pp. 4602 - 4608, http://dx.doi.org/10.1002/cncr.32476

Arun BK; Han HS; Kaufman B; Wildiers H; Friedlander M; Ayoub J-P; Puhalla SL; Bach BA; Dudley M; Ratajczak CK; Maag D; Dieras V, 2019, 'First-line veliparib plus carboplatin/paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: Planned subgroup analysis from the phase 3 BROCADE3 trial', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, presented at 42nd Annual San Antonio Breast Cancer Symposium, TX, San Antonio, 09 December 2019 - 14 December 2019, http://dx.doi.org/10.1158/1538-7445.SABCS19-PD4-01

Piskorz A; Robertson D; Lin KK; Morris J; Mann E; Oza A; Coleman RL; O'Malley DM; Friedlander M; Cragun JM; Ma L; Giordano H; McNeish IA; Swisher E; Wason J; Brenton JD, 2019, 'Abstract GMM-048: CTDNA RESPONSE TO THE PARP INHIBITOR RUCAPARIB PREDICTS PROGRESSION-FREE SURVIVAL AND BEST OVERALL RESPONSE ON THE ARIEL2 TRIAL', in Clinical Cancer Research, American Association for Cancer Research (AACR), http://dx.doi.org/10.1158/1557-3265.ovcasymp18-gmm-048

Moore K; Colombo N; Scambia G; Kim B-G; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza A; Gonzalez-Martin A; Aghajanian C; Bradley W; Mathews C; Liu J; Lowe ES; Bloomfield R; DiSilvestro P, 2019, 'MAINTENANCE OLAPARIB AFTER PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED ADVANCED OVARIAN CANCER AND A BRCA MUTATION: EFFICACY BY THE TIMING OF SURGERY AND RESIDUAL TUMOUR STATUS FOLLOWING UPFRONT OR INTERVAL CYTOREDUCTIVE SURGERY IN THE PHASE III SOLO1 TRIAL', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, BMJ PUBLISHING GROUP, pp. A14 - A15, http://dx.doi.org/10.1136/ijgc-2019-ESGO.17

Desai J; Markman B; Friedlander M; Gan H; Horvath L; Townsend A; Millward M; Jameson M; Yen C-J; Hou M-M; Hou J; Wu J; Liang L; Deva S, 2019, 'Abstract CT084: Long-term exposure (LTE) to Tislelizumab, an investigational anti-PD-1 antibody, in a first-in-human Phase I study', in Clinical Trials, American Association for Cancer Research, presented at Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA, http://dx.doi.org/10.1158/1538-7445.sabcs18-ct084

Deva S; Lee J-S; Lin C-C; Yen C-J; Millward M; Chao Y; Keam B; Jameson M; Hou M-M; Kang Y-K; Markman B; Lu C-H; Rau K-M; Lee K-H; Horvath L; Friedlander M; Hill A; Wu J; Hou J; Desai J, 2018, 'A phase Ia/Ib trial of tislelizumab, an anti-PD-1 antibody (ab), in patients (pts) with advanced solid tumors', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SWITZERLAND, Geneva, presented at ESMO Immuno-Oncology Congress, SWITZERLAND, Geneva, 13 December 2018 - 16 December 2018, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000459294800077&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Sandhu S; Hill A; Gan H; Friedlander M; Voskoboynik M; Barlow P; Townsend A; Song J; Zhang Y; Liang L; Desai J, 2018, 'Tislelizumab, an anti-PD-1 antibody, in patients with urothelial carcinoma (UC): Results from an ongoing phase I/II study', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SWITZERLAND, Geneva, pp. 28 - 28, presented at ESMO Immuno-Oncology Congress, SWITZERLAND, Geneva, 13 December 2018 - 16 December 2018, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000459294800083&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Goh JC; Baron-Hay S; Bonaventura T; Buck M; Dean A; Friedlander M; Gao B; Mileshkin L; Oehler MK; Steer C; Vi N; Goble S; Grechko N; Monk BJ; Kristeleit RS, 2018, 'ATHENA (GOG-3020/ENGOT-ov45): A randomised, double-blind, placebo-controlled, phase 3 study of rucaparib plus nivolumab following front-line platinum-based chemotherapy in ovarian cancer', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 196 - 196, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000449544200343&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Moore KN; Colombo N; Scambia G; Kim B-G; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza AM; Gonzalez-Martin A; Aghajanian C; Bradley W; Lowe ES; Bloomfield R; DiSilvestro P, 2018, 'Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, GERMANY, Munich, pp. 727 - 727, presented at 43rd ESMO Congress (ESMO), GERMANY, Munich, 19 October 2018 - 23 October 2018, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000459277305017&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Antill Y; Barlow-Stewart K; Friedlander M; Meiser B; Do J; Nevin S; Gleeson M; Kentwell M; Tucker K; Taylor N; Kirk J, 2018, 'Changing a nation: The development and evaluation of a training program for oncology health professionals in the provision of genetic testing for ovarian cancer patients.', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, BMJ PUBLISHING GROUP, pp. 202 - 203, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000471153100137&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Moore KN; Colombo N; Scambia G; Kim BG; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza AM; González-Martín A; Aghajanian C; Bradley W; Lowe ES; Bloomfield R; DiSilvestro P, 2018, 'Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial', in Annals of oncology : official journal of the European Society for Medical Oncology, pp. viii727, http://dx.doi.org/10.1093/annonc/mdy424.041

Mileshkin L; Sivakumaran T; Grant P; Na L; Friedlander M; Webb P; Au-Yeung G, 2018, 'COMPARING THE IMPACT OF DOSE REDUCTIONS/ DELAYS ON OVARIAN CANCER OUTCOMES USING THREE WEEKLY OR DOSE DENSE CARBOPLATIN/ PACLITAXEL REGIMENS IN THE NATIONAL PROSPECTIVE OPAL COHORT', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, BMJ PUBLISHING GROUP, pp. 770 - 770, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000471152401334&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Webb PM; Beesley V; deFazio A; Obermair A; Grant PT; Nagle C; Friedlander M, 2018, 'The hidden burden of anxiety and depression in ovarian cancer: A prospective study from diagnosis.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 01 June 2018 - 05 June 2018, http://dx.doi.org/10.1200/JCO.2018.36.7_suppl.155

Webb PM; deFazio A; Obermair A; Grant PT; Friedlander M; Beesley V; Nagle C, 2018, 'The Ovarian cancer Prognosis And Lifestyle (OPAL) study.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 01 June 2018 - 05 June 2018, http://dx.doi.org/10.1200/JCO.2018.36.7_suppl.88

Webb PM; Beesley V; Nagle C; Grant PT; deFazio A; Obermair A; Friedlander M, 2018, 'When will I feel normal again? Quality of life trajectories after first-line chemotherapy for ovarian cancer.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 01 June 2018 - 05 June 2018, http://dx.doi.org/10.1200/JCO.2018.36.7_suppl.172

Sackeyfio A; Nussey F; Friedlander M; Pujade-Lauraine E, 2018, 'Comparative efficacy and tolerability of the PARP inhibitors, olaparib 300 mg tablets BID, niraparib 300 mg capsules QD and rucaparib 600 mg tablets BID as maintenance treatment in BRCA-mutated (BRCAm) platinum-sensitive relapsed ovarian', in GYNECOLOGIC ONCOLOGY, ACADEMIC PRESS INC ELSEVIER SCIENCE, pp. 43 - 44, http://dx.doi.org/10.1016/j.ygyno.2018.04.094

Vergote I; Hanker LC; Floquet A; Rau J; Kim J-W; Izquierdo EO; Friedlander M; Pignata S; Fujiwara K; Colombo N; Mirza MR; Monk BJ; Moertl M; Calvert P; Herzog TJ; Jackisch C; Meunier J; Lee J-Y; Belau AK; Du Bois A, 2018, 'AGO-OVAR 16: A phase III study to evaluate the efficacy and safety of pazopanib (PZ) monotherapy versus placebo in women who have not progressed after first line chemotherapy for epithelial ovarian, fallopian tube, or primary peritoneal cancer-Overall survival (OS) results', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.5518

Friedlander M; Chan JK; Java J; Armstrong DK; Markman M; Herzog TJ; Monk BJ; Backes FJ; Secord AA; Bonebrake AJ; Rose PG; Tewari KS; Mannel RS; Lentz SS; Geller MA; Copeland LJ, 2018, 'Characterization and predictors of long term (>= 10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer patients.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.5556

Sivakumaran T; Mileshkin LR; Grant PT; Friedlander M; Webb PM; Au-Yeung G, 2018, 'Comparing the impact of dose reductions and delays on ovarian cancer patient outcomes with three-weekly versus dose dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.5568

Friedlander M; King M; Nagle C; Obermair A; Grant PT; deFazio A; Webb PM, 2018, 'Getting the most out of follow-up: A prospective study using the Measure of Ovarian Symptoms and Treatment concerns (MOST) symptom index to evaluate and track adverse effects (AEs) and detect symptoms of recurrence in patients with ovarian cancer (OC) following first line chemotherapy (1LT).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.10062

Wilson MK; Chawla T; Wang L; Friedlander M; Oza AM; Lheureux S, 2018, 'Inter and intra-observer variability with the assessment of RECIST in ovarian cancer.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.5555

Banerjee SN; Tang M; O'Connell R; Clamp AR; Lord R; Mullassery VM; Hall M; Gourley C; Bonaventura T; Goh JC; Sykes P; Grant PT; McNally O; Edmondson RJ; Friedlander M, 2018, 'PARAGON: A phase 2 study of anastrozole (An) in patients with estrogen receptor(ER) and / progesterone receptor (PR) positive recurrent/metastatic granulosa cell tumors/sex-cord stromal tumors (GCT) of the ovary', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.5524

Sjoquist KM; Mileshkin LR; Ananda S; Shannon CM; Bowtell D; Yip S; Espinoza D; Goh JC; Harrison ML; Plebanski M; Gebski V; Stockler MR; Livingstone K; Tang M; Friedlander M, 2018, 'REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal (IP) bevacizumab (bev) for recurrent ascites in advanced, chemotherapy-resistant, epithelial ovarian cancer (CR-EOC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.10097

Webb PM; Beesley V; deFazio A; Obermair A; Grant PT; Nagle CM; Friedlander M, 2018, 'The hidden burden of anxiety and depression in ovarian cancer: A prospective longitudinal study from diagnosis.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.10081

Nayar N; Lawrence NJ; Stockler MR; Martin AJ; Yip S; Wong N; Yeung A; Friedlander M; Mazhar D; Pashankar F; Quinn DI; McDermott R; Walker R; Winstanley M; Hanning FJ; Weickhardt AJ; Stevanovic AG; Davis ID; Toner GC; Grimison PS, 2018, 'P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poorrisk metastatic germ cell tumors (GCTs).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, CA, San Francisco, presented at Genitourinary Cancers Symposium, CA, San Francisco, 08 February 2018 - 10 February 2018, http://dx.doi.org/10.1200/JCO.2018.36.6_suppl.TPS574

Sandhu SK; Hill AG; Gan HK; Friedlander M; Voskoboynik M; Barlow P; Townsend AR; Song J; Zhang Y; Shen Z; Qi Q; Desai J, 2018, 'Preliminary results from patients with urothelial carcinoma (UC) in a phase 1A/1B study of bgb-A317, an anti-PD-1 monoclonal antibody.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, CA, San Francisco, presented at Genitourinary Cancers Symposium, CA, San Francisco, 08 February 2018 - 10 February 2018, http://dx.doi.org/10.1200/JCO.2018.36.6_suppl.445

Friedlander M; Meniawy T; Markman B; Mileshkin LR; Harnett P; Millward M; Lundy J; Freimund AE; Norris C; Wu J; Paton V; Wang L; Gao B, 2018, 'A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, presented at ASCO-SITC Clinical Immuno-Oncology Symposium, CA, San Francisco, 25 January 2018 - 27 January 2018, http://dx.doi.org/10.1200/JCO.2018.36.5_suppl.48

Wong N; Nayar N; Lawrence N; Stockler M; Martin A; Yip S; Yeung A; Friedlander M; Mazhar D; Pashankar F; Quinn D; Walker R; Winstanley M; Weickhardt A; Hanning F; Stevanovic A; Davis I; Toner G; Grimison P, 2017, 'P3BEP (ANZUP 1302): An International Randomised Phase III Trial of Accelerated Versus Standard BEP Chemotherapy for Adult and Pediatric Male and Female Patients With Intermediate and Poor-Risk Metastatic Germ Cell Tumours (GCTS)', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 168 - 168, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000413954500265&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Penson R; Kaminsky-Forrett M-C; Ledermann J; Brown C; Plante M; Korach J; Huzarski T; Lista AGDL; Pisano C; Friedlander M; Colombo N; Gropp-Meier M; Nakai H; Sonke GS; Kim J-W; Vergote I; Allen A; Pujade-Lauraine E, 2017, 'Efficacy of olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by lines of prior chemotherapy: Phase III SOLO2 trial (ENGOT Ov-21)', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SPAIN, Madrid, presented at 42nd European-Society-for-Medical-Oncology Congress (ESMO), SPAIN, Madrid, 08 September 2017 - 12 September 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000411324002120&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Ritchie G; Gasper H; Man J; Lord S; Friedlander M; Lee C; Marschner I, 2017, 'is objective response rate (ORR) a valid primary endpoint in phase 2 trials (Ph2t) of immune checkpoint inhibitors (ICI) for advanced solid cancers?', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SPAIN, Madrid, presented at 42nd European-Society-for-Medical-Oncology Congress (ESMO), SPAIN, Madrid, 08 September 2017 - 12 September 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000411324003027&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Meniawy T; Richardson G; Townsend A; Desai J; Gan H; Friedlander M; Horvath L; Jameson MB; Sandhu S; Wu Z; Qin Z; Kang K; Markman B, 2017, 'Preliminary results from a subset of patients (pts) with advanced ovarian cancer (OC) in a dose-escalation/expansion study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb)', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SPAIN, Madrid, presented at 42nd European-Society-for-Medical-Oncology Congress (ESMO), SPAIN, Madrid, 08 September 2017 - 12 September 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000411324001049&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Peate M; Jayasinghe Y; Allingham C; Hucker A; Kemertzis M; Meiser B; Friedlander M; Hickey M, 2017, 'Supporting fertility decision-making: the role of decision aids in oncofertility.', in PSYCHO-ONCOLOGY, WILEY, pp. 166 - 166, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000407688900459&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Friedlander M; Pujade-Lauraine E; Ledermann JA; Penson RT; Oza AM; Korach J; Huzarski T; Poveda A; Pignata S; Colombo N, 2017, 'Treatment with Maintenance Olaparib Significantly Improves Progression-Free Survival in Patients with Platinum-Sensitive Relapsed Ovarian Cancer: Results of SOLO2 Study', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 51 - 51, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000427542700014&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Desai J; Gan H; Barrow C; Jameson MB; Solomon B; Atkinson V; Haydon A; Millward M; Begbie S; Brown M; Markman B; Patterson W; Hill A; Horvath L; Nagrial A; Richardson G; Jackson C; Friedlander M; Gibbs D; Parente P; Yang J; Wang L; Chen Y; Luo L, 2017, 'Abstract CT002: A Phase IB study of RAF dimer inhibitor BGB-283 in patients with B-RAF or K-RAS/N-RAS mutated solid tumors', in Cancer Research, American Association for Cancer Research (AACR), pp. CT002 - CT002, http://dx.doi.org/10.1158/1538-7445.am2017-ct002

Rohr I; Hilpert V; Heitz F; Fehm T; Canzler U; Friedlander M, 2017, 'Symptom burden and outcomes in patients with platinum resistant/refractory (PRR) and potentially platinum sensitive ROC receiving ≥3 lines of chemotherapy (PPS ≥3) – The Gynecologic Cancer Intergroup (GCIG) Symptom Benefit Study (SBS)', in Geburtshilfe und Frauenheilkunde, Georg Thieme Verlag KG, presented at Jahrestagung der Österreichischen Gesellschaft für Gynäkologie und Geburtshilfe (OEGGG) gemeinsam mit der Bayerischen Gesellschaft für Geburtshilfe und Frauenheilkunde e.V (BGGF), 14 June 2017 - 17 June 2017, http://dx.doi.org/10.1055/s-0037-1602307

Friedlander M; Meniawy T; Markman B; Mileshkin LR; Harnett PR; Millward M; Lundy J; Freimund AE; Norris C; Mu S; Wu J; Paton VE; Wang L; Gao B, 2017, 'A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, IL, Chicago, 02 June 2017 - 07 June 2017, http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.3013

Back to profile page